Focusing on insights based on real-world data (RWD) related to drug lifecycle and medical practice, Verana Health (San Francisco) has just hauled in $150 million Series E funding.
Verana Health’s current fundraising total is $288.8 million, according to CrunchBase.
Johnson & Johnson Innovation (JJDC) and Novo Growth led the most recent funding round.
Also joining the funding round was Merck Global Health Innovation Fund, THVC and Breyer Capital.
Prior investors include GV (formerly Google Ventures), Casdin Capital and Brook Byers.
Founded in 2018, Verana Health has established exclusive partnerships with three specialty medical societies and several Big Pharma companies. It also has customers in biotech and biopharma, and also supports contract research organizations.
Its RWD network includes input from more than 20,000 healthcare providers. In addition, the network consists of data from more than 90 million de-identified patients.
The company will use part of the funding to build up its offerings related to natural language processing to parse electronic health record (EHR) notes.
Filed Under: clinical trials, Drug Discovery
Tell Us What You Think!
You must be logged in to post a comment.